Related references
Note: Only part of the references are listed.Long-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome A Collaborative Analysis of Individual Patient Data From the FRISC II, ICTUS, and RITA-3 Trials (FIR)
Peter Damman et al.
CIRCULATION (2012)
Acute Coronary Events
Armin Arbab-Zadeh et al.
CIRCULATION (2012)
American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)
Marc P. Bonaca et al.
CIRCULATION (2012)
Third universal definition of myocardial infarction
Kristian Thygesen et al.
EUROPEAN HEART JOURNAL (2012)
Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction
Sergio Leonardi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
Benjamin M. Scirica et al.
LANCET (2012)
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Promises of PAR-1 Inhibition in Acute Coronary Syndrome
Sergio Leonardi et al.
CURRENT CARDIOLOGY REPORTS (2012)
Identifying Patients at High Risk of a Cardiovascular Event in the Near Future Current Status and Future Directions: Report of a National Heart, Lung, and Blood Institute Working Group
Kim A. Eagle et al.
CIRCULATION (2010)
Safety and Exploratory Efficacy of the Novel Thrombin Receptor (PAR-1) Antagonist SCH530348 for Non-ST-Segment Elevation Acute Coronary Syndrome
Shinya Goto et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2010)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale
Robert A. Harrington et al.
AMERICAN HEART JOURNAL (2009)
Prognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes An Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Abhiram Prasad et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Richard C. Becker et al.
LANCET (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Universal definition of myocardial infarction
Kristian Thygesen et al.
CIRCULATION (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical end points in coronary stent trials - A case for standardized definitions
Donald E. Cutlip et al.
CIRCULATION (2007)
Share Paper
